JP2020519904A - 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用 - Google Patents

腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用 Download PDF

Info

Publication number
JP2020519904A
JP2020519904A JP2020511871A JP2020511871A JP2020519904A JP 2020519904 A JP2020519904 A JP 2020519904A JP 2020511871 A JP2020511871 A JP 2020511871A JP 2020511871 A JP2020511871 A JP 2020511871A JP 2020519904 A JP2020519904 A JP 2020519904A
Authority
JP
Japan
Prior art keywords
igfbp7
timp
renal
risk score
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519904A5 (enExample
Inventor
マクファーソン，ポール
カンプフ，ジェームズ，パトリック
Original Assignee
アスチュート メディカル，インコーポレイテッド
アスチュート メディカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスチュート メディカル，インコーポレイテッド, アスチュート メディカル，インコーポレイテッド filed Critical アスチュート メディカル，インコーポレイテッド
Publication of JP2020519904A publication Critical patent/JP2020519904A/ja
Publication of JP2020519904A5 publication Critical patent/JP2020519904A5/ja
Priority to JP2023052930A priority Critical patent/JP2023082094A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
JP2020511871A 2017-05-07 2018-05-07 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用 Pending JP2020519904A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023052930A JP2023082094A (ja) 2017-05-07 2023-03-29 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502728P 2017-05-07 2017-05-07
US62/502,728 2017-05-07
PCT/US2018/031425 WO2018208684A1 (en) 2017-05-07 2018-05-07 Use of insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 in the management of renal replacement therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023052930A Division JP2023082094A (ja) 2017-05-07 2023-03-29 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用

Publications (2)

Publication Number Publication Date
JP2020519904A true JP2020519904A (ja) 2020-07-02
JP2020519904A5 JP2020519904A5 (enExample) 2021-08-19

Family

ID=64105628

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511871A Pending JP2020519904A (ja) 2017-05-07 2018-05-07 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用
JP2023052930A Pending JP2023082094A (ja) 2017-05-07 2023-03-29 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023052930A Pending JP2023082094A (ja) 2017-05-07 2023-03-29 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用

Country Status (5)

Country Link
US (1) US20210025875A1 (enExample)
EP (1) EP3621987A4 (enExample)
JP (2) JP2020519904A (enExample)
CN (1) CN110753700A (enExample)
WO (1) WO2018208684A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628843A (en) 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA3158996C (en) 2013-01-17 2024-06-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN110709103B (zh) 2017-04-05 2024-02-02 机敏医药股份有限公司 用于生物学样品中具有改善的性能的timp2的测定法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014070935A1 (en) * 2012-10-31 2014-05-08 Astute Medical, Inc. Quantitative lateral flow assay
JP2015064371A (ja) * 2009-12-20 2015-04-09 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2016164854A1 (en) * 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
CN108139409B (zh) * 2015-10-08 2020-07-24 豪夫迈·罗氏有限公司 当在外科手术之前测量时用于预测aki的风险的igfbp7

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015064371A (ja) * 2009-12-20 2015-04-09 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2014070935A1 (en) * 2012-10-31 2014-05-08 Astute Medical, Inc. Quantitative lateral flow assay
WO2016164854A1 (en) * 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANITHA VIJAYAN: "Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment", AM J KIDNEY DIS, vol. 68, no. 1, JPN6022011791, 2016, pages 19 - 28, XP055753571, ISSN: 0004931860, DOI: 10.1053/j.ajkd.2015.12.033 *
ERIC A.J. HOSTE: "Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers", NEPHROL DIAL TRANSPLANT, vol. 29, JPN6022011783, 18 September 2014 (2014-09-18), pages 2054 - 2061, ISSN: 0004931861 *
HORST P. KIERDORF: "Continuous Renal Replacement Therapies Versus Intermittent Hemodialysis in Acute Renal Failure: What", AMERICAN JOURNAL OF KIDNEY DISEASES, vol. Vol.28 No.5 Suppl 3, JPN6022011787, November 1996 (1996-11-01), pages 90 - 96, ISSN: 0004931864 *
KEVIN PILARCZYK: "Urinary [TIMP-2]*[IGFBP7] for early prediction of acute kidney injury after coronary artery bypass s", ANN. INTENSIVE CARE, vol. 5, JPN6022011784, 2015, pages 50, ISSN: 0004931862 *
KIANOUSH KASHANI: "Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption", CLIN CHEM LAB MED, vol. 55, no. 8, JPN6022011789, 11 January 2017 (2017-01-11), pages 1074 - 1089, ISSN: 0004737615 *
MARLIES OSTERMANN: "Patient Selection and Timing of Continuous Renal Replacement Therapy", BLOOD PURIF, vol. 42, JPN6022011786, 26 August 2016 (2016-08-26), pages 224 - 237, XP055753681, ISSN: 0004931863, DOI: 10.1159/000448506 *
NANDKISHOR S. CHINDARKAR: "Reference intervals of urinary acute kidney injury (AKI)markers [IGFBP7]・[TIMP2] in apparently heal", CLINICA CHIMICA ACTA, vol. 452, JPN6022011782, 10 November 2015 (2015-11-10), pages 32 - 37, XP029365983, ISSN: 0004931859, DOI: 10.1016/j.cca.2015.10.029 *

Also Published As

Publication number Publication date
CN110753700A (zh) 2020-02-04
JP2023082094A (ja) 2023-06-13
EP3621987A4 (en) 2021-01-06
US20210025875A1 (en) 2021-01-28
WO2018208684A1 (en) 2018-11-15
EP3621987A1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
US12203941B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2023082094A (ja) 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用
US11243217B2 (en) Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
JP7068256B2 (ja) 腎損傷および腎不全の診断および予後のための方法および組成物
US9551720B2 (en) Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
US10935548B2 (en) Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
US20210041469A1 (en) Methods and compositions for diagnosis and prognosis of sepsis
MX2014002146A (es) Métodos y composiciones para diagnóstico y pronóstico de lesión renal e insuficiencia renal.
EP2882767B1 (en) Evaluating renal injury using hyaluronic acid
Class et al. Patent application title: METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE Inventors: Lakhmir S. Chawla (Mclean, VA, US) Paul Mcpherson (Encinitas, CA, US) Paul Mcpherson (Encinitas, CA, US)
AU2021381364A1 (en) Methods and compositions for treatment of renal injury and renal failure
HK1224741A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1248808A1 (zh) 用於肾损伤和肾衰竭的诊断和预後的方法和组合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221129